125 related articles for article (PubMed ID: 23711792)
21. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
[TBL] [Abstract][Full Text] [Related]
22. [Ipilimumab treatment of metastatic melanoma].
Ghasemi H; Schmidt H; Stolle LB
Ugeskr Laeger; 2015 Jan; 177(2A):108-9. PubMed ID: 25612993
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
24. Molecularly targeted therapy for melanoma: current reality and future options.
Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
[TBL] [Abstract][Full Text] [Related]
25. The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: opportunities and unanswered questions.
Murrell J; Board R
Cancer Treat Rev; 2013 Dec; 39(8):833-8. PubMed ID: 23845462
[TBL] [Abstract][Full Text] [Related]
26. Management of metastatic melanoma.
Tawbi HA; Kirkwood JM
Semin Oncol; 2007 Dec; 34(6):532-45. PubMed ID: 18083377
[TBL] [Abstract][Full Text] [Related]
27. [Molecular-target therapy for advanced malignant melanoma].
Takahashi S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):19-25. PubMed ID: 23306915
[TBL] [Abstract][Full Text] [Related]
28. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.
Natarajan N; Telang S; Miller D; Chesney J
Drugs; 2011 Jul; 71(10):1233-50. PubMed ID: 21770473
[TBL] [Abstract][Full Text] [Related]
29. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
Weber JS; Samlowski WE; Gonzalez R; Ribas A; Stephenson J; O'Day S; Sato T; Dorr R; Grenier K; Hersh E
Cancer; 2010 Aug; 116(15):3683-91. PubMed ID: 20564083
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of therapies for melanoma.
Johnston KM; McPherson E; Osenenko K; Vergidis J; Levy AR; Peacock S
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):229-42. PubMed ID: 25703441
[TBL] [Abstract][Full Text] [Related]
31. Side effects and toxicities of targeted therapies in stage IV melanoma.
Ascierto PA; Bastholt L; Hersey P; Cinat G; Eggermont AM; Hauschild A; Espinosa E; Robert C
Am J Ther; 2015; 22(1):44-53. PubMed ID: 24185314
[TBL] [Abstract][Full Text] [Related]
32. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
Maul LV; Weichenthal M; Kähler KC; Hauschild A
J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
[TBL] [Abstract][Full Text] [Related]
33. Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape.
Zigler M; Villares GJ; Lev DC; Melnikova VO; Bar-Eli M
Am J Clin Dermatol; 2008; 9(5):307-11. PubMed ID: 18717605
[TBL] [Abstract][Full Text] [Related]
34. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
Marabondo S; Kaufman HL
Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820
[TBL] [Abstract][Full Text] [Related]
35. Therapy for metastatic melanoma: the past, present, and future.
Finn L; Markovic SN; Joseph RW
BMC Med; 2012 Mar; 10():23. PubMed ID: 22385436
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
37. Unresectable and Metastatic Melanoma of the Skin: Literature Review of Clinical Trials and Efficacy Endpoints Since 2000.
Jin S; Mishra-Kalyani PS; Sridhara R
Ther Innov Regul Sci; 2019 Jan; 53(1):59-70. PubMed ID: 29714599
[TBL] [Abstract][Full Text] [Related]
38. Treatment algorithm of metastatic mucosal melanoma.
Wang X; Si L; Guo J
Chin Clin Oncol; 2014 Sep; 3(3):38. PubMed ID: 25841464
[TBL] [Abstract][Full Text] [Related]
39. Translocation of BBAP from the cytoplasm to the nucleus reduces the metastatic ability of vemurafenib-resistant SKMEL28 cells.
Thang ND; Minh NV; Huong PT
Mol Med Rep; 2017 Jan; 15(1):317-322. PubMed ID: 27922665
[TBL] [Abstract][Full Text] [Related]
40. PCC0208018 exerts antitumor effects by activating effector T cells.
Ge M; Hu Z; Chen X; Du G; Wang H; Liu R; Ye L; Tian J
Int J Immunopathol Pharmacol; 2019; 33():2058738419843366. PubMed ID: 30968715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
